Larry L. Wood - May 7, 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP & Grp President TAVR & SSH
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
May 7, 2023
Transactions value $
-$359,841
Form type
4
Date filed
5/9/2023, 07:50 PM
Previous filing
May 4, 2023
Next filing
May 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $0 +5.42K +2.64% $0.00 210K May 7, 2023 Direct F1
transaction EW Common Stock Tax liability -$229K -2.58K -1.23% $88.74 208K May 7, 2023 Direct
transaction EW Common Stock Tax liability -$131K -1.47K -0.71% $88.74 206K May 8, 2023 Direct
holding EW Common Stock 496 May 7, 2023 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -5.42K -78.48% $0.00 1.49K May 7, 2023 Common Stock 5.42K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.